We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Soon to Consider Potentially Market-Busting Immunotherapy, Sintilimab, Which Has Only Been Tested in China
FDA Soon to Consider Potentially Market-Busting Immunotherapy, Sintilimab, Which Has Only Been Tested in China
The FDA will soon decide whether Eli Lilly’s and Innovent Biologics’ immunotherapy sintilimab can get the go-ahead in the U.S. for the treatment of lung cancer.